Please login to the form below

Not currently logged in
Email:
Password:

Jazz Pharma

This page shows the latest Jazz Pharma news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

Daily Brief: Jazz Pharma and Ultragenyx approvals, Autonomous AI in retinopathy

The latest from pharma, biotech and healthcare. Jazz Pharma gains EU approval for niche AML treatment. ... or AML with myelodysplasia-related changes,” said Daniel Swisher, president and chief operating officer at Jazz Pharmaceuticals.

Latest news

  • Jazz Pharma bags FDA approval for rare disease drug Jazz Pharma bags FDA approval for rare disease drug

    The US FDA has given the green light for Jazz Pharma's Defitelio, adding another product to the company's stable of rare disease therapies. ... Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013.

  • Baxter buoys cancer presence with $900m Oncaspar deal Baxter buoys cancer presence with $900m Oncaspar deal

    disease therapy sector, with suggestions Shire or Jazz Pharma may be interested in the unit.

  • Shire drawn into Luxembourg tax haven exposé Shire drawn into Luxembourg tax haven exposé

    Investigations into Luxembourg's tax activities certainly stretch back several years, and this is not the first time that a pharma company has been implicated in the practice. ... Other pharma companies appearing in an ICIJ database of leaked documents -

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    Jazz expects to achieve revenues of around $870m this year, with around $570m of that total coming from Xyrem. ... Meanwhile, Jazz CEO Bruce Cozadd said the acquisition "would add a new orphan product that has potential for short- and long-term revenue

  • Jazz fibromyalgia drug not approvable

    The US Food and Drug Administration has notified Jazz Pharmaceuticals that fibromyalgia treatment JZP-6 is not approvable in its current form. ... Jazz Pharmaceuticals has been notified by the US Food and Drug Administration (FDA) that the New Drug

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    $11m. Servier. Sorrento. $821m. $28m. Jazz Pharma. Pfenex. $181m. $15m. ONO Pharma. ... Sprint BioScience/ Petre Pharma. PIP4K2a inhibitor programme. Licence. 240. Pfenex/ Jazz Pharmaceuticals.

  • Pharma deals in March 2015 Pharma deals in March 2015

    The other deal of interest is the re-emergence of EUSA Pharma with products acquired from Jazz Pharmaceuticals. ... investor, Essex Woodlands, has bought back products worth $27m and the EUSA Pharma name from Jazz for an undisclosed amount.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics